• Louise Gorham, Stefan Just, and Henri Doods.
• Boehringer Ingelheim Pharma GmbH & Co. KG, Dept. CNS Diseases Research Germany, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany. Electronic address: louise_catherine_josephine.gorham@boehringer-ingelheim.com.
• Neurosci. Lett. 2014 Jun 24;573:35-9.

AbstractSomatostatin (sst) is a cyclic neuropeptide known to have inhibitory roles in the central nervous system. It exerts its biological effects via the activation of the 5 sst receptor subtypes, which belong to the family of G-protein coupled receptors (GPCR). This peptide has analgesic properties, specifically via the activation of the sst4 receptor subtype. Although this is established, the precise molecular mechanisms causing this have not yet been fully elucidated. This research aimed to identify a possible anti-nociceptive mechanism, showing functional links to the transient receptor potential vanilloid type 1 (TRPV1) within the pain processing pathway. Calcium imaging and whole cell voltage clamp experiments were conducted on DRG neurons prepared from adult rats, utilizing capsaicin stimulations and the sst4 receptor specific agonist J-2156. The complete Freund's adjuvant (CFA) inflammatory pain model was used to examine if effects are augmented in pain conditions. The sst4 receptor agonist J-2156 was able significantly to inhibit capsaicin induced calcium and sodium influx, where the effect was more potent after CFA treatment. This inhibition identifies a contributory molecular mechanism to the analgesic properties of sst4 receptor activation.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

44 keywords...

hide…